Sinco Pharmaceuticals Holdings Limited provided consolidated earning guidance for the year ended 31 December 2023. For the year, the group is expected to record a net profit attributable to equity holders of the Company for the current year of approximately RMB 42.0 million, representing a decrease of approximately RMB 27.5 million or approximately 39.6%, as compared to the net profit attributable to equity holders of the Company of approximately RMB 69.5 million for the year ended 31 December 2022. Based on the information currently available, the Board considers that the decrease of the net profit was primarily due to the increase of the administration expenses as the Group expanded the business operation in research and manufacturing of aesthetic medicine segment and the medical beauty segment in the Current Year.